Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
about
Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantationUGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaksEndoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation.Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Time-dependent clearance of mycophenolic acid in renal transplant recipientsPopulation pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients.Individualization of mycophenolate mofetil dose in renal transplant recipients.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune diseaseMaximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis.Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation.Renal Function and NODM in De Novo Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS.Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil.Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients.Role of enterohepatic recirculation in drug disposition: cooperation and complications.Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
P2860
Q34152549-2193B27F-EB91-4370-8627-2ABF79816681Q34180482-DE71CFB5-20A6-4F12-BD04-F00D48E11879Q34984788-303E72A8-6E35-4C2A-858A-1DB6D8608C83Q35759067-75440736-7387-493F-8BE9-72AC24CB3E5BQ35779482-218B41BA-633F-4A32-B6EC-D6DB0B8CF20DQ35967888-6A4D25BA-92E0-407F-847A-989A12C28504Q36024478-137F9143-C7EC-4EF6-B4FC-5538980CC8F9Q36036364-12AE6136-26BE-4E73-BACC-051CCA5175D7Q36111207-200EF85F-4F46-478E-8E6F-3105FC875C49Q36336060-6A68C27D-EE62-4ADE-85F2-3CB83EB2E5E9Q36383851-C42674C3-0656-48E4-B02B-54DF6B67CCA4Q36407345-8BBFBFC7-F837-4535-9E9E-10E1AF18210FQ36788423-F4D7DB1C-2BB8-4A32-B09F-7049C55E1242Q36792638-D8597950-DD09-4689-894F-0D741E4859EAQ37737279-C6D317CE-B04F-412D-AC22-5D649DABE2CFQ37818144-D92D12C2-2576-4150-AC3F-04B40B1746C8Q37956717-F06AE54F-F305-49FA-A2E8-863EBAF9EDC8Q38087925-C67C7713-DC74-4255-9227-3253B5EA58DFQ38170321-3CDAA71B-51B6-4BB2-A738-3D46DD560BAFQ38610665-12C2CB67-9AB9-4A8B-AD20-9A69A9B3BAF2Q38720831-76C369A3-B2D9-43E5-B1CB-BC553ABE3014Q38768108-69513102-A744-435B-B057-E1F8D84C9397Q39338374-E308E727-5546-4F02-ACFB-4C118EB87428Q40086776-162E3FE8-4C27-4C67-8218-F1B84F45F5D8Q41767570-2EF56AF1-0EC0-4BF5-BD28-9949F5042F66Q44600058-6F536701-64F9-41A9-B463-2068048B3D21Q45353017-EAED0F76-0B18-46C6-8BA6-EEEB641B4331Q46006810-89558226-DCB2-4C27-9E3E-F87478D6FA3DQ46040442-54827A28-ED5D-4B65-BBCD-BFEF8F2CB765Q46140802-5FBC1E51-709D-433B-8E7E-B03B8DF3B811Q46578287-7BB57A93-59C1-4B6A-BDA1-57AA9E22D428Q46673746-990F5FC0-E217-4F6D-94CE-BE79992D8669Q51913689-DA081D5C-B3E8-4AF6-A31D-1619C899AB01Q53791202-5F333F68-90D6-400B-8CFD-1C1401AD06E6
P2860
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Characterizing the role of ent ...... by pharmacokinetic modelling.
@ast
Characterizing the role of ent ...... by pharmacokinetic modelling.
@en
type
label
Characterizing the role of ent ...... by pharmacokinetic modelling.
@ast
Characterizing the role of ent ...... by pharmacokinetic modelling.
@en
prefLabel
Characterizing the role of ent ...... by pharmacokinetic modelling.
@ast
Characterizing the role of ent ...... by pharmacokinetic modelling.
@en
P2093
P2860
P1476
Characterizing the role of ent ...... s by pharmacokinetic modelling
@en
P2093
Eduard Scholten
Eric van Kan
Jacqueline König-Quartel
Jan den Hartigh
Johan de Fijter
Leendert Paul
Serge Cremers
P2860
P304
P356
10.1111/J.1365-2125.2005.02398.X
P407
P577
2005-09-01T00:00:00Z